Sonoma Other Current Liab vs Non Currrent Assets Other Analysis
| SNOA Stock | USD 2.70 0.04 1.50% |
Sonoma Pharmaceuticals financial indicator trend analysis is much more than just breaking down Sonoma Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sonoma Pharmaceuticals is a good investment. Please check the relationship between Sonoma Pharmaceuticals Other Current Liab and its Non Currrent Assets Other accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.
Other Current Liab vs Non Currrent Assets Other
Other Current Liab vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sonoma Pharmaceuticals Other Current Liab account and Non Currrent Assets Other. At this time, the significance of the direction appears to have no relationship.
The correlation between Sonoma Pharmaceuticals' Other Current Liab and Non Currrent Assets Other is 0.02. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Sonoma Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Sonoma Pharmaceuticals' Other Current Liab and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Sonoma Pharmaceuticals are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Other Current Liab i.e., Sonoma Pharmaceuticals' Other Current Liab and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.02 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Other Current Liab
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Sonoma Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sonoma Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.At present, Sonoma Pharmaceuticals' Selling General Administrative is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.24, whereas Discontinued Operations is forecasted to decline to about 568.6 K.
| 2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 4.5M | 4.7M | 5.5M | 5.1M | Total Revenue | 13.3M | 12.7M | 14.6M | 11.3M |
Sonoma Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Sonoma Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonoma Pharmaceuticals fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 15.0M | 18.8M | 16.2M | 14.7M | 17.0M | 15.3M | |
| Total Stockholder Equity | 5.4M | 8.7M | 8.0M | 6.1M | 7.1M | 8.7M | |
| Net Debt | (1.5M) | (6.0M) | (3.0M) | (2.5M) | (2.3M) | (2.4M) | |
| Cash | 4.2M | 7.4M | 3.8M | 3.1M | 2.8M | 5.3M | |
| Cash And Short Term Investments | 4.2M | 7.4M | 3.8M | 3.1M | 2.8M | 5.3M | |
| Common Stock Shares Outstanding | 99.8K | 132.7K | 169.7K | 454.5K | 522.7K | 262.8K | |
| Liabilities And Stockholders Equity | 15.0M | 18.8M | 16.2M | 14.7M | 17.0M | 15.3M | |
| Total Current Assets | 13.0M | 16.4M | 13.8M | 12.5M | 14.4M | 12.6M | |
| Other Assets | 850K | 875K | 1.5M | 1.5M | 1.8M | 1.8M | |
| Other Stockholder Equity | 189.2M | 197.4M | 200.9M | 203.2M | 233.7M | 148.5M | |
| Total Liab | 9.6M | 10.1M | 8.3M | 8.6M | 9.9M | 6.9M | |
| Short Long Term Debt Total | 2.7M | 1.4M | 849K | 608K | 547.2K | 519.8K | |
| Other Current Liab | (2.6M) | (2.0M) | (2.5M) | (2.8M) | (2.5M) | (2.4M) | |
| Total Current Liabilities | 4.1M | 5.8M | 3.7M | 3.7M | 3.3M | 3.7M | |
| Property Plant And Equipment Net | 1.1M | 879K | 906K | 651K | 585.9K | 958.7K | |
| Current Deferred Revenue | 319K | 1.3M | 160K | 478K | 430.2K | 673.3K | |
| Retained Earnings | (179.3M) | (184.4M) | (189.5M) | (194.3M) | (174.9M) | (183.7M) | |
| Accounts Payable | 1.8M | 1.6M | 841K | 607K | 546.3K | 519.0K | |
| Non Current Assets Total | 2.0M | 2.4M | 2.4M | 2.2M | 2.5M | 2.9M | |
| Non Currrent Assets Other | 875K | 707K | 578K | 396K | 455.4K | 584.7K | |
| Net Receivables | 2.8M | 2.4M | 2.6M | 2.9M | 3.3M | 2.3M | |
| Non Current Liabilities Total | 5.5M | 4.3M | 4.5M | 4.9M | 5.6M | 5.9M | |
| Inventory | 2.5M | 2.7M | 2.9M | 2.7M | 3.1M | 1.7M | |
| Other Current Assets | 3.4M | 4.0M | 4.5M | 3.8M | 4.4M | 4.6M | |
| Property Plant And Equipment Gross | 1.1M | 2.6M | 2.9M | 3.0M | 3.5M | 3.7M | |
| Accumulated Other Comprehensive Income | (4.6M) | (4.3M) | (3.4M) | (2.7M) | (2.5M) | (2.6M) | |
| Short Term Debt | 1.1M | 1.1M | 943K | 719K | 647.1K | 781.0K | |
| Property Plant Equipment | 365K | 1.1M | 879K | 906K | 815.4K | 906.4K | |
| Other Liab | 245K | 3.7M | 4.0M | 4.4M | 5.0M | 5.3M | |
| Net Tangible Assets | 8.7M | 5.4M | 8.7M | 8.0M | 7.2M | 9.0M | |
| Short Long Term Debt | 596K | 808K | 431K | 323K | 371.5K | 366.2K | |
| Capital Lease Obligations | 769K | 559K | 418K | 285K | 327.8K | 478.6K | |
| Net Invested Capital | 7.3M | 9.5M | 8.4M | 6.5M | 5.8M | 7.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.